University Journal of Surgery and Surgical Specialities
Email this article 
Hide
Show all
BIOCHEMICAL MARKERS IN ORAL CANCER
Abstract
Biochemical markers or Tumour markers are substances produced by tumour cells or by other cells within the body in response to cancer or certain benign conditions. Tumour markers include nucleic acids, proteins, peptides, enzymatic changes, antibodies, metabolites, lipids, and carbohydrates. These markers may be detected within exfoliated or distributed cells, or as circulating agents within the peripheral blood, saliva or plasma that helps in identifying key biological molecules or markers that could be linked to cancer development. They also play a major role in risk assessment, screening, recurrence prediction, and indicating prognosis, indicating invasion/metastasis and monitoring therapeutic responses of cancer. For these reasons it is essential to have knowledge about the biomarkers. This review paper briefly describes about potential molecular markers in oral neoplasia.
Full Text:
PDFReferences
Qin R, Steel A, Fazel N. Oral mucosa biology and salivary biomarkers. Clinics in dermatology. 2017 Sep 1;35(5):477-83.
Strimbu, Kyle, and Jorge A. Tavel. “What Are Biomarkers?” Current opinion in HIV and AIDS 5.6(2010): 463–466. PMC. Web. 5 Aug. 2015.
Sahu P, Pinkalwar N, Dubey RD, Paroha S, Chatterjee S, Chatterjee T. Biomarkers: an emerging tool for diagnosis of a disease and drug development. Asian Journal of Research in Pharmaceutical Sciences. 2011 Mar 28;1(1):09-16.
Williams HK. Molecular pathogenesis of oral squamous carcinoma. Molecular Pathology. 2000 Aug;53(4):165.
Santosh AB, Jones T, Harvey J. A review on oral cancer biomarkers: Understanding the past and learning from the present. Journal of cancer research and therapeutics. 2016 Apr 1;12(2):486.
Sahibzada HA, Khurshid Z, Khan RS, Naseem M, Siddique KM, Mali M, Zafar MS. Salivary IL-8, IL-6 and
TNF-α as potential diagnostic biomarkers for oral cancer. Diagnostics. 2017 Jun;7(2):21.
Herceg Z, Hainaut P. Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. Mol Oncol 2007;1:26‑41.
Mishra A, Verma M. Cancer biomarkers: Are we ready for the prime time? Cancers (Basel) 2010;2:190‑208
Suresh MR. Classification of tumor markers. Anticancer research. 1996;16(4B):2273-7.
Duffy MJ. Evidence for the clinical use of tumour markers. Annals of clinical biochemistry. 2004 Sep 1;41(5):370-7.
Lavanya R, Mamatha B, Waghray S, Chaitanya NC, Reddy MP, Bau DG. Role of Tumor Markers in Oral Cancer: An Overview. Journal of Advances in Medicine and Medical Research. 2016 May 4:1-
Barak V, Goike H, Panaretakis KW, EinarssonR. Clinical utility of cytokeratins as tumor markers. ClinBiochem2004;37:529‑40.
Bancroft JD, Marilyn G. Immunohistochemistry anddiagnostic pathology, Theory and Practice ofHistological Techniques. 5th ed.ition: Elsevier; USA,2002. p. 537‑52.
Malati T. Tumour markers: An overview. Indian Journal of Clinical Biochemistry. 2007 Sep 1;22(2):17-31.
Dbouk HA, Tawil A, Nasr F, Kandakarjian L, Abou ‑Merhi R. Significance of CEA and VEGF as diagnostic markers of colorectal cancer in lebanese patients. Open Clin Cancer J 2007;1:1‑5.
Sultan MK, Sadatullah S, Shaik MA. Have biomarker smade their mark? A brief review of dental biomarkers. Journal of Dental Research and Review. 2014 Jan1;1(1):37.
Angadi PV, Krishnapillai R (2007) Cyclin D1 expression in oral squamous cell carcinoma and verrucous carcinoma: correlation with histological differentiation.OralSurg Oral Med Oral Pathol Oral RadiolEndod 103 :e30-5.
Altmannsberger M, Weber K, Droste R, Osborn M. Desmin is a specific marker for rhabdomyosarcomas of human and rat origin. Am J Pathol1985;118:85‑95.
Am. De Jong AS, van Kessel‑van Vark M, Albus‑LutterCE,vanRaamsdonk W, Voûte PA. Skeletal muscle actin astumor marker in the diagnosis of rhabdomyosarcoma inchildhood. J SurgPathol1985;9:467‑74
Leader M, Patel J, Collins M, Henry K. Myoglobin: Anevaluation of its role as a marker of rhabdomyosarcomas.Br J Cancer 1989;59:106‑9
Gaynor R, Irie R, Morton D, Herschman HR. S100protein is present in cultured human malignantmelanomas. Nature 1980;286:400‑1 .
Weiss AP, Dorfman HD. S ‑ 100 protein in humancartilage lesions. J Bone Joint Surg Am 1986;68:521‑6.
Trerè D (2000) AgNORsstainig and quantification.Micron 31:127-131.
Derenzini M, Pession A, Farabegoli F, Trerè D, BadialiM, et al. (1989) Relationship between interphasicnucleolar organizer regions and growth rate in two neurolastoma cell lines. Am J Pathol 134: 925–932.
Piffkò J, Bànkfalvi A, Ofner D, Bryne M, Rasch D, et al.(1997) Prognostic value of histobiological factors(malignancy grading and AgNOR content) assessed at theinvasive tumour front of oral squamous cell carcinomas.Br J Cancer 75:1543-6.
López-Blanc SA, Collet AM, Gandolfo MS, FemopaseF,Hernández SL, et al. (2009) Nucleolar organizer regions(AgNOR) and subepithelial vascularization as fieldcancerization markers in oral mucosa biopsies ofalcoholic and smoking patients. Oral Surg Oral Med OralPathol Oral RadiolEndod 108:747-753.
Kumar M, SARIN SH K. Biomarkers of diseases Inmedicine.Current Trends in Science – Platinum JubileeSpecial. 2009;403-417.
Karley D, Gupta D, Tiwari A. Biomarkers: The Future ofMedical Science to Detect Cancer. J Mol Biomark Diagn.2011;2:118.
Hiyama E, Hiyama K. Telomerase as tumor marker.Cancer Lett. 2003; 194:221–233.
St John MA, Li Y, Zhou X, Denny P, Ho CM,Montemagno C, Shi W, Qi F, Wu B, Sinha U, Jordan R,Wolinsky L, Park NH, Liu H, Abemayor E, Wong DT.Interleukin 6 andinterleukin 8 as potential biomarkersfor oral cavity and oropharyngeal squamous cellcarcinoma. Arch Otolaryngol Head Neck Surg 2004;130: 929-935 [PMID: 15313862 DOI:10.1001/archotol.130.8.929.5]
SahebJamee M, Eslami M, AtarbashiMoghadam F,Sarafnejad A. Salivary concentration of TNFalpha, IL1alpha, IL6, and IL8 in oral squamous cell carcinoma.Med Oral Patol Oral Cir Bucal 2008; 13: E292-E295[PMID: 18449112]
Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM.Matrix metalloproteinases: biologic activity and clinicalimplications. J Clin Oncol 2000; 18: 1135-1149 [PMID:10694567]
Ravanti L, Kähäri VM. Matrix metalloproteinases inwound repair (review). Int J Mol Med 2000; 6: 391-407[PMID: 10998429 DOI: 10.3892/ijmm.6.4]
Cathcart J, Pulkoski-Gross A, Cao J. Targeting MatrixMetalloproteinases in Cancer: Bringing New Life to OldIdeas. Genes Dis 2015; 2: 26-34 [PMID: 26097889 DOI:10.1016/j.genedis.2015]
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
An Initiative of The Tamil Nadu Dr MGR Medical University